Loading…
TScan Therapeutics, Inc. is projected to rise to $1.08 by 2027, a +1% move from its current price of $1.07. TCRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.03 | $1.07 | $1.11 | +0.05% |
| May 30 | $1.02 | $1.07 | $1.13 | +0.09% |
| May 31 | $1.00 | $1.07 | $1.14 | +0.14% |
| Jun 1 | $0.9941 | $1.07 | $1.16 | +0.18% |
| Jun 2 | $0.9858 | $1.07 | $1.17 | +0.23% |
| Jun 3 | $0.9783 | $1.07 | $1.18 | +0.27% |
| Jun 4 | $0.9715 | $1.07 | $1.19 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9715 | $1.07 | $1.19 | +0.32% |
| Week 2 | $0.9352 | $1.08 | $1.24 | +0.64% |
| Week 3 | $0.9089 | $1.08 | $1.28 | +0.96% |
| Week 4 | $0.8877 | $1.08 | $1.32 | +1.28% |
| Week 5 | $0.8698 | $1.09 | $1.36 | +1.60% |
| Week 6 | $0.8542 | $1.09 | $1.39 | +1.92% |
| Week 7 | $0.8403 | $1.09 | $1.42 | +2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell (TCR-T) therapies for cancer in the United States. The lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
The company also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, it develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc.
to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. (TCRX) is a Healthcare stock with a current price of $1.06 and a market cap of $69.27M. It holds the 4441st rank by market capitalization.
The stock trades in a near-term context within a 30-day range of $0.8143 to $1.38, with the current price near the middle of that band. The forecast indicates a path from Neutral in 2026 toward stronger bullish momentum in later years, with 2026 projected average price of $1.06 and a 2026-2035 trajectory that gradually lifts toward 2030 average of $1.49 and a 2050 average of $4.11.
Key year-by-year highlights show 2026 min $0.91, avg $1.06, max $1.32 (ROI 0, sentiment Neutral); 2030 avg $1.49 with max $2.38 (ROI 40.7, sentiment Bullish); 2040 avg $2.04 with max $3.96 (ROI 92.6, sentiment Bullish); and 2050 avg $4.11 with max $8.93 (ROI 288, sentiment Bullish). The trend suggests a bullish long-term outlook beyond 2030, with higher potential upside.
A major floor 35.8% below — a decisive break under it would weaken the trend.
The nearest floor, 10.0% below — buyers have tended to step in here.
The nearest ceiling, 33.6% above — a clean break opens room to run.
A major ceiling 51.5% above — clearing it would confirm fresh momentum.
Key TCRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TCRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.04 | Buy | $1.05 | Buy |
| MA 10 | $1.04 | Buy | $1.07 | Buy |
| MA 20 | $1.12 | Sell | $1.10 | Sell |
| MA 50 | $1.11 | Sell | $1.11 | Sell |
| MA 100 | $1.09 | Sell | $1.15 | Sell |
| MA 200 | $1.33 | Sell | $1.38 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.23 | Neutral |
| Stoch RSI (14) | 50.38 | Neutral |
| CCI (20) | -43.11 | Neutral |
| Williams %R (14) | -63.97 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -15.08 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 36.03 | Neutral |
| TRIX (15) | -0.25 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 58.84 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 1.07 | Sell |
| ADX (14) | 13.19 | Neutral |
| ATR (14) | 0.04 | Info |
The near-term technical picture is Bearish. The RSI(14) stands at 50, with the 50-day simple moving average at $1.11 and the 200-day simple moving average at $1.34, framing a cautious outlook.
Support is identified at $0.963 and resistance at $1.43, offering a defined trading range as momentum develops. Over the last 30 days, the stock traded between $0.8143 and $1.38, and the annualized volatility is 80, underscoring meaningful swings even within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.91 | $1.07 | $1.33 | 0% | Neutral | |
| $0.8219 | $1.08 | $1.51 | +1% | Neutral | |
| $0.817 | $1.11 | $1.63 | +4% | Neutral | |
| $0.8093 | $1.14 | $1.74 | +6% | Neutral | |
| $1.04 | $1.51 | $2.38 | +41% | Bullish | |
| $1.04 | $1.55 | $2.51 | +45% | Bullish | |
| $0.9954 | $1.52 | $2.52 | +42% | Bullish | |
| $1.04 | $1.63 | $2.75 | +52% | Bullish | |
| $0.8925 | $1.43 | $2.47 | +34% | Bullish | |
| $0.9913 | $1.63 | $2.85 | +52% | Bullish | |
| $1.18 | $2.14 | $4.06 | +100% | Bullish | |
| $1.92 | $4.23 | $8.95 | +296% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.91 | $1.07 | $1.26 | +0.00% |
| June 2026 | $0.9415 | $1.11 | $1.36 | +4.19% |
| July 2026 | $0.9307 | $1.12 | $1.38 | +0.03% |
| August 2026 | $0.8855 | $1.07 | $1.35 | -3.98% |
| September 2026 | $0.8836 | $1.08 | $1.37 | +0.55% |
| October 2026 | $0.8922 | $1.09 | $1.41 | +1.68% |
| November 2026 | $0.8499 | $1.05 | $1.36 | -4.15% |
| December 2026 | $0.817 | $1.01 | $1.33 | -3.30% |
Click any year to see its month-by-month TCRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The TCRX price prediction for 2026 points to an average of $1.07 (low $0.91, high $1.33) — a potential gain of 0% on today's $1.07. Price action looks broadly range-bound.
In 2027, TCRX is projected to trade between $0.8219 and $1.51, averaging $1.08 — a potential gain of +1% from today's $1.07. That is up +1% on the projected 2026 average. A consolidation phase looks the most probable path here.
TScan Therapeutics, Inc.'s 2028 outlook centres on $1.11, within a $0.817 to $1.63 range. That is up +3% on the projected 2027 average. That marks a +4% change versus current levels. Price action looks broadly range-bound.
By 2029, TCRX could reach as high as $1.74, with a base case around $1.14 and support toward $0.8093 — roughly +6% from $1.07. A consolidation phase looks the most probable path here.
Expect TCRX to range from $1.04 to $2.38 through 2030. The $1.51 average target implies a +41% move from current prices. That is up +33% on the projected 2029 average. Momentum favours further upside here.
The TCRX price prediction for 2031 points to an average of $1.55 (low $1.04, high $2.51) — a potential gain of +45% on today's $1.07. Buyers look set to stay in control over this stretch.
In 2032, TCRX is projected to trade between $0.9954 and $2.52, averaging $1.52 — a potential gain of +42% from today's $1.07. That is -2% versus the projected 2031 average. Momentum favours further upside here.
TScan Therapeutics, Inc.'s 2033 outlook centres on $1.63, within a $1.04 to $2.75 range. That is up +7% on the projected 2032 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, TCRX could reach as high as $2.47, with a base case around $1.43 and support toward $0.8925 — roughly +34% from $1.07. Momentum favours further upside here.
Expect TCRX to range from $0.9913 to $2.85 through 2035. The $1.63 average target implies a +52% move from current prices. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The TCRX price prediction for 2040 points to an average of $2.14 (low $1.18, high $4.06) — a potential gain of +100% on today's $1.07. Momentum favours further upside here.
In 2050, TCRX is projected to trade between $1.92 and $8.95, averaging $4.23 — a potential gain of +296% from today's $1.07. That is up +98% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TCRX today (≈ 934.579439 TCRX) could be worth
$3,957.61
+$2,957.61 (+296%) by 2050 · US Dollar
Based on the average projected TCRX price of $4.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TCRXwould be worth at today's price.
$1,000 invested in TCRX on May 27, 2025 (≈ 699.300725 TCRX) would be worth
$748.25
-$251.75 (-25.2%) today · 0.75× · US Dollar
Based on a TCRX entry price of $1.43 vs. today's $1.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.995 | $1,075.38 | +7.5% |
| 1 month ago | $1.31 | $816.79 | -18.3% |
| 3 months ago | $1.11 | $963.96 | -3.6% |
| 6 months ago | $1.11 | $963.96 | -3.6% |
| 1 year ago | $1.43 | $748.25 | -25.2% |
| All time (4.9y) ago | $10.5 | $101.9 | -89.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TCRX forecast.
Our base-case forecast reaches $2.10 around 2040.
Implied market cap at $2.10: $128.26M
The multi-year forecast points to a bullish trajectory beginning in the 2030s and extending through 2050. In 2030, the average price is projected at $1.49 with a max of $2.38 and an ROI of 40.7, signaling a stronger growth phase compared with prior years and a shift in sentiment to Bullish.
In 2040, the average price rises to $2.04 with a max of $3.96 and an ROI of 92.6, reinforcing a continued bullish path as the model anticipates higher valuation and stronger upside.
By 2050, the average price approaches $4.11 with a max of $8.93 and an ROI of 288, maintaining a Bullish sentiment. These estimates imply a substantial long-term upside, though they remain subject to market and regulatory dynamics, execution progress, and other uncertainties.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $1.49 with a max of $2.38 and a minimum of $1.01, with an ROI of 40.7 and a Bullish sentiment.
The forecast indicates a transition to Bullish from 2030 onward, with a 2050 average price of $4.11 and ROI of 288, suggesting meaningful upside. However, these are estimates and not guarantees.
The 2050 forecast shows an average price of $4.11 and a max of $8.93 with an ROI of 288, indicating the potential to reach around $4 on average, depending on market conditions.
The 2026 forecast lists min $0.91, avg $1.06, max $1.32, with Neutral sentiment.
The near-term picture is Bearish with RSI(14) at 50, SMA50 at $1.11, SMA200 at $1.34, support at $0.963, and resistance at $1.43. The 30-day range is $0.8143–$1.38, and annualized volatility is 80.
TScan Therapeutics, Inc. Community Discussion
0Share your TScan Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.